We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

5 hedge funds and large institutions have $517K invested in Avenue Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less capital invested

Capital invested by funds: $771K → $517K (-$254K)

38% less funds holding

Funds holding: 8 → 5 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
5
Holders Change
-3
Holders Change %
-37.5%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BRWA
B. Riley Wealth Advisors
Florida
+$184K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$86.7K
3
VF
Virtu Financial
New York
+$71.4K
4
UBS Group
UBS Group
Switzerland
+$45.9K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$258K
2
Goldman Sachs
Goldman Sachs
New York
-$89K
3
SIM
Spark Investment Management
New York
-$69K
4
TRCT
Tower Research Capital (TRC)
New York
-$41K
5
Morgan Stanley
Morgan Stanley
New York
-$5.1K

ATXI Hedge Fund Activity: Q4 2017 in Review

5 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2017, worth a combined $517K — down 33% from $771K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ATXI and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was B. Riley Wealth Advisors, adding an estimated $184K. The largest seller was Millennium Management, exiting entirely with an estimated $258K sold.

  • 5 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2017, down from 8 in Q3 2017.
  • Funds reported $517K of Avenue Therapeutics, Inc. Common Stock stock for Q4 2017, down 33% quarter-over-quarter.
  • 2 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2017 and 5 closed out, a net change of -3 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2017 was B. Riley Wealth Advisors, an estimated $184K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2017 was Millennium Management, an estimated $258K sold.

Based on aggregated 13F filings for Q4 2017.